Clinical Trials Logo

Clinical Trial Summary

In the research study an observation of patients with wet age-related macular degeneration (wet AMD) will be performed.

The term observational study indicates that the current course of therapy and the associated circumstances will be recorded. In this study, no medical care is changed. Also, no new drugs are tested.

This study is being conducted in about 30 centers in Germany. A total of approximately 500 patients will be enrolled. The study is designed for a period of 12 months.

At the beginning and end of the study the physician will document the patient data. Therefore will be used information from the patient records and documented visits. If such information is not available in the study center, the otherwise attending ophthalmologist will be consulted about the vision acuity values and visits in the observation period.

Furthermore, patients are asked to participate in three telephone interviews and fill out during their visits to the study center a short questionnaire about their current vision and their well-being. In the telephone interviews will be discussed with the patient about his wet AMD disease and its treatment, its experience and its perspectives as well as any problems occur.


Clinical Trial Description

n/a


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01448538
Study type Observational
Source Bayer
Contact
Status Completed
Phase N/A
Start date August 2011
Completion date February 2014

See also
  Status Clinical Trial Phase
Terminated NCT04049266 - A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. Phase 2/Phase 3
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Terminated NCT05038371 - Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration
Completed NCT03278262 - The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting
Completed NCT04982484 - Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment
Completed NCT00590694 - Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments Phase 2/Phase 3
Completed NCT04516278 - A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders Phase 3
Completed NCT03844074 - A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) Phase 3
Recruiting NCT05637255 - A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD) Phase 2
Completed NCT04756310 - Study of Nutritional Supplementation in Patients With Unilateral Wet AMD N/A
Active, not recruiting NCT05112861 - A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders Phase 3
Enrolling by invitation NCT03999801 - Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy Phase 2
Terminated NCT03699618 - Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration
Completed NCT01666821 - A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population N/A
Completed NCT03022292 - The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy Phase 4
Completed NCT02944227 - Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration Phase 4
Terminated NCT03452527 - Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) Phase 2
Completed NCT01243086 - OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab Phase 2
Completed NCT03823300 - A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) Phase 3
Recruiting NCT04420923 - Optimizing the Treatment Strategy for Age-related Macular Degeneration N/A